Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)

NCT02944383 is registered in ClinicalTrials.gov with NeuroBo Pharmaceuticals Inc. as lead sponsor.

NCT NCT02944383
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02944383 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Lead sponsor
NeuroBo Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2016
Completion date
May 9, 2018
Enrollment
91 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

mixed dyslipidaemia, severe hypertriglyceridemia